## **National Board of Examinations**

Question Paper Name :	DNB Pharmacology Paper1
Subject Name :	DNB Pharmacology Paper1
Creation Date :	2021-08-25 17:09:01
Duration :	180
Total Marks :	100
Display Marks:	No

## **DNB Pharmacology Paper1**

**Group Number:** 1 Group Id: 327187277 **Group Maximum Duration:** 0 **Group Minimum Duration:** 180 **Show Attended Group?:** No **Edit Attended Group?:** No Break time: 0 **Group Marks:** 100 Is this Group for Examiner?: No

## **DNB Pharmacology Paper1**

Section Id: 327187280
Section Number: 1

Section type: Offline

Mandatory or Optional: Mandatory

Number of Questions: 10

Number of Questions to be attempted: 10

Section Marks: 100

**Enable Mark as Answered Mark for Review and** 

**Clear Response:** 

Yes

Sub-Section Number: 1

**Sub-Section Id:** 327187284

**Question Shuffling Allowed:** No

Question Number: 1 Question Id: 3271871290 Question Type: SUBJECTIVE

**Correct Marks: 10** 

Discuss various targets of drug action along with suitable examples. [10]

Question Number: 2 Question Id: 3271871291 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) Enumerate various pharmacokinetic parameters of a drug. [4]

b) Discuss their clinical significance by giving suitables. [4]

c) Describe the factors influencing the frequency of dosing of drug to a patient. [2]

Question Number: 3 Question Id: 3271871292 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) What do you understand by the term "therapeutic index"? [5]

b) How will you determine therapeutic window for a new experimental drug? [5]

Question Number: 4 Question Id: 3271871293 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) Describe the term pharmacoeconomics. [2]

b) Enumerate the criteria used to analyse cost and benefit. [4]

c) Discuss the various methods for pharmacoeconomic analysis. [4]

Question Number: 5 Question Id: 3271871294 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) What are CYP 450 families and their role in drug metabolism? [5]

b) Discuss the clinical significance of enzyme inhibition and its therapeutic implications. [5]

Question Number: 6 Question Id: 3271871295 Question Type: SUBJECTIVE

**Correct Marks: 10** 

Discuss in brief the requirement and methods for dose adjustment in renal diseases. [10]

Question Number: 7 Question Id: 3271871296 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) Role of pharmacokinetic/ pharmacodynamic modelling in drug research and development. [5]

b) Biased agonism. [5]

Question Number: 8 Question Id: 3271871297 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) What is pharmacovigilance and what is its importance? [5]

b) Discuss various methods of causality assessment with their advantages and limitations. [5]

Question Number: 9 Question Id: 3271871298 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) Off-label use of drugs with examples. [5]

b) Applications of biotechnology in medicine. [5]

Question Number: 10 Question Id: 3271871299 Question Type: SUBJECTIVE

**Correct Marks: 10** 

a) Genetic polymorphism. [5]

b) Rational use of medicine. [5]